- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05529277
Implementing Dementia Care Management Into Routine Care in the Region Siegen-Wittgenstein (RoutineDeCM)
Dementia Care Management in Der Routineversorgung am Beispiel Der Region Siegen-Wittgenstein (RoutineDeCM)
Dementia Care Management (DeCM) is an evidence-based model of care in Germany. It has proven its efficacy and cost-effectiveness. However it has not been implemented into routine care so far.
The aim of this trial is to implement Dementia Care Management into routine care in a selected region in Germany and evaluate the process of implementation as well as the effect of Dementia Care Management on participants.
Recruited in regular routine care n=60 people with cognitive impairment and/ or their cares will receive Dementia Care Management provided by specifically trained and qualified dementia care managers for 6 months.
Data will be assessed and analysed prior to the implementation, immediately after having received the intervention and at a later time point.
The effect of the intervention on person-oriented health care outcomes wil be analysed as well as factors associated with that.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jochen René Thyrian, Prof. Dr.
- Phone Number: 7592 +49383486
- Email: rene.thyrian@dzne.de
Study Contact Backup
- Name: Melanie Boekholt
- Phone Number: 7593 +49383486
- Email: melanie.boekholt@dzne.de
Study Locations
-
-
MV
-
Greifswald, MV, Germany, 17489
- Active, not recruiting
- Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)
-
-
NRW
-
Siegen, NRW, Germany, 57068
- Active, not recruiting
- University of Siegen
-
Siegen, NRW, Germany, 57072
- Recruiting
- Caritasverband Siegen-Wittgenstein eV
-
Contact:
- Charlotte Boes
-
Principal Investigator:
- Charlotte Boes
-
Siegen, NRW, Germany, 57076
- Recruiting
- Alzheimer Gesellschaft Siegen-Wittgenstein eV
-
Contact:
- Stefanie Kremer
-
Principal Investigator:
- Stefanie Kremer
-
Siegen, NRW, Germany, 57076
- Recruiting
- Kreisklinikum Siegen, Kliniken für Neurologie und Psychiatrie
-
Contact:
- Martin Grond, Prof.Dr.
-
Principal Investigator:
- Martin Grond, Prof. Dr.
-
Witten, NRW, Germany, 58453
- Active, not recruiting
- Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- person with cognitive impairment living in household
- living in the region of Siegen-Wittgenstein
- written informed consent
Exclusion Criteria:
- institutionalisation of person with cognitive impairment
- lacking sufficient communication skills
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Dyad of person with cognitive impairment and caregiver
Households identified in routine care receiving a home-based Dementia Care Management.
|
Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
unmet needs
Time Frame: 12 months after baseline assessment
|
generic standardized assessment implemented as computer-assisted intervention management system (CMS) addresses caregiver burden, medical needs, home care needs, psychosocial needs (depression, sleep quality, pain, hearing, seeing, teeth problems, dementia related problems caused by PwD, medical aids).
Adding the needs indicated provides a number of unmet needs.
|
12 months after baseline assessment
|
unmet needs
Time Frame: 6 months after baseline assessment
|
generic standardized assessment implemented as computer-assisted intervention management system (CMS) addresses caregiver burden, medical needs, home care needs, psychosocial needs (depression, sleep quality, pain, hearing, seeing, teeth problems, dementia related problems caused by person with dementia (PwD), medical aids).
Adding the needs indicated provides a number of unmet needs.
|
6 months after baseline assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antidementia drug treatment
Time Frame: 12 months after baseline assessment
|
A computer-based home medication review (HMR) encompasses all medications used by the study participants and includes questions about compliance, adverse effects and drug administration.
The collection of primary data on medication in the context of the HMR includes both prescription drugs and over-the-counter drugs.
The assignment was then integrated using a master file of the Pharmaceutical Index.
The following antidementia drugs will be considered: donepezil (N06AD02), rivastigmine (N06AD03), galantamine (N06AD04) and memantine (N06AX01)
|
12 months after baseline assessment
|
Antidementia drug treatment
Time Frame: 6 months after baseline assessment
|
A computer-based home medication review (HMR) encompasses all medications used by the study participants and includes questions about compliance, adverse effects and drug administration.
The collection of primary data on medication in the context of the HMR includes both prescription drugs and over-the-counter drugs.
The assignment was then integrated using a master file of the Pharmaceutical Index.
The following antidementia drugs will be considered: donepezil (N06AD02), rivastigmine (N06AD03), galantamine (N06AD04) and memantine (N06AX01)
|
6 months after baseline assessment
|
Neuropsychiatric Symptoms
Time Frame: 6 months after baseline assessment
|
Neuropsychiatric Inventory (NPI; Cummings 1997); The NPI represents an interview by proxy on twelve dimensions of neuropsychiatric behaviors, i.e. delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities.
The presence (0= no, 1= yes) is asked.
If present, the severity (rated 1 through 3; mild to severe) and frequency (1 to 4, rarely to very often) of each neuropsychiatric symptom are rated on.
Thus the score for each dimension ranges from 0 = not present, 1= mildly and rarely to 12 = severe and often.
A total NPI score is calculated as the sum of the frequency by severity scores ofeach domain range: 0 to 144, the higher the more neuropsychiatric symptomatic).
|
6 months after baseline assessment
|
Caregiver Burden
Time Frame: 6 months after baseline assessment
|
The revised version of the Zarit-Burden Inventory (ZBI; Zarit et al., 1980) will be used.The revised version ZBI is a caregiver self-report measure to examine burden which is associated with functional/behavioural impairments and home care situation.
It contains 22 items using a 5-point scale.
Response options range from 0 (Never) to 4 (Nearly Always).Total scores range from 0 indicating low burden to 88 indicating high burden.
|
6 months after baseline assessment
|
Caregiver Burden
Time Frame: 12 months after baseline assessment
|
The revised version of the Zarit-Burden Inventory (ZBI; Zarit et al., 1980) will be used.The revised version ZBI is a caregiver self-report measure to examine burden which is associated with functional/behavioural impairments and home care situation.
It contains 22 items using a 5-point scale.
Response options range from 0 (Never) to 4 (Nearly Always).Total scores range from 0 indicating low burden to 88 indicating high burden.
|
12 months after baseline assessment
|
Neuropsychiatric Symptoms
Time Frame: 12 months after baseline assessment
|
Neuropsychiatric Inventory (NPI; Cummings 1997); The NPI represents an interview by proxy on twelve dimensions of neuropsychiatric behaviors, i.e. delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities.
The presence (0= no, 1= yes) is asked.
If present, the severity (rated 1 through 3; mild to severe) and frequency (1 to 4, rarely to very often) of each neuropsychiatric symptom are rated on.
Thus the score for each dimension ranges from 0 = not present, 1= mildly and rarely to 12 = severe and often.
A total NPI score is calculated as the sum of the frequency by severity scores of each domain range: 0 to 144, the higher the more neuropsychiatric symptomatic).
|
12 months after baseline assessment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cognition
Time Frame: 6 months after baseline assessment
|
The Mini Mental State Examination (MMSE; Cockrell & Folstein, 1988) will be used.
The MMSE is a 30-point questionnaire to measure cognitive impairment.
The questions are grouped into seven categories, each representing a different cognitive domain or function: Orientation to time (5 points); Orientation to place (5 points); Registration of three words (3 points); Attention and Calculation (5 points); Recall of three words (3 points); Language (8 points) and Visual Construction (1 point).
Scores of 25-30 out of 30 are considered normal; 21-24 as mild, 10-20 as moderate and <10 as severe impairment.
|
6 months after baseline assessment
|
cognition
Time Frame: 12 months after baseline assessment
|
The Mini Mental State Examination (MMSE; Cockrell & Folstein, 1988) will be used.
The MMSE is a 30-point questionnaire to measure cognitive impairment.
The questions are grouped into seven categories, each representing a different cognitive domain or function: Orientation to time (5 points); Orientation to place (5 points); Registration of three words (3 points); Attention and Calculation (5 points); Recall of three words (3 points); Language (8 points) and Visual Construction (1 point).
Scores of 25-30 out of 30 are considered normal; 21-24 as mild, 10-20 as moderate and <10 as severe impairment.
|
12 months after baseline assessment
|
frailty
Time Frame: 6 months after baseline assessment
|
Frailty will be assessed using the Edmonton frailty scale (EFS; Rolfson et al. 2006) will be used.
The EFS is reliable tool in geriatric medicine to assess the frailty of older patients on the domains Cognition, General health status, Functional independence, Social support, Medication use, Nutrition, Mood, Continence and Functional performance.
|
6 months after baseline assessment
|
frailty
Time Frame: 12 months after baseline assessment
|
Frailty will be assessed using the Edmonton frailty scale (EFS; Rolfson et al. 2006) will be used.
The EFS is reliable tool in geriatric medicine to assess the frailty of older patients on the domains Cognition, General health status, Functional independence, Social support, Medication use, Nutrition, Mood, Continence and Functional performance.
|
12 months after baseline assessment
|
(health-related) quality of life
Time Frame: 6 months after baseline assessment
|
Quality of life will be assessed using the the health-related quality of life questionnaire (EQ-5D), a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal.
|
6 months after baseline assessment
|
(health-related) quality of life
Time Frame: 12 months after baseline assessment
|
Quality of life will be assessed using EQ-5D, a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal.
|
12 months after baseline assessment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jochen René Thyrian, Prof. Dr., German Center for Neurodegenerative Diseases (DZNE)
- Principal Investigator: Bernhard Holle, Dr., German Center for Neurodegenerative Diseases (DZNE)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GR025
- ZMI1-2521FSB907 (Other Grant/Funding Number: Federal Ministery of Health (BMG))
- BB110/22 (Other Identifier: Ethics Comittee of the Universitymedicine Greifswald)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on Dementia Care Management
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesUnknown
-
RANDNational Institute on Aging (NIA); Alzheimer's Association; Olive View-UCLA Education...CompletedDementiaUnited States
-
German Center for Neurodegenerative Diseases (DZNE)University Medicine Greifswald; Techniker Krankenkasse; Federal Joint Committee; AOK Nordost and other collaboratorsActive, not recruitingDementia | Nurse's Role | Nurse Physician RelationsGermany
-
German Center for Neurodegenerative Diseases (DZNE)German Federal Ministry of Education and Research; University Medicine Greifswald and other collaboratorsCompletedNeurodegenerative Diseases | Cognitive Impairment | DementiaGermany
-
German Center for Neurodegenerative Diseases (DZNE)University Medicine GreifswaldActive, not recruiting
-
Corporal Michael J. Crescenz VA Medical CenterCompleted
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
University of California, Los AngelesPatient-Centered Outcomes Research Institute; Yale University; University of... and other collaboratorsCompleted
-
Chang Gung Memorial HospitalChang Gung University of Science and TechnologyCompleted
-
Chang Gung Memorial HospitalChang Gung University of Science and Technology; National Science and Technology...Not yet recruiting